KCT0000057招募中未知
Single-center, open-labeled, three-arm parallel group trial of the role of alterations in bacterial microbiota on gastric carcinogenesis
Hanyang University Seoul Hospital0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational Study
入排标准
- 年龄范围
- 18(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •patients for gastroscopy
排除标准
- •Patients with previous gastric surgery, gastric perforation, upper gastrointestinal bleeding, hemodynamic instability, and those with refusal of consent to the study
研究者
相似试验
已完成
3 期
A clinical trial to Assess theImmunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine DTwP-Hib-HepB in Indian infantsCTRI/2011/11/002118ovartis Healthcare Pvt Ltd Vaccines Division175
进行中（未招募）
不适用
Safety and Tolerability of a Fully Liquid Pentavalent Vaccine Quinvaxem® when Administered to Indian Infants at 6, 10, and 14 Weeks of AgeProphilaxis against diphtheria, tetanus, pertussis, hepatitis B and invasive Haemophilus influenzae type b disease.EUCTR2014-005309-18-Outside-EU/EEAovartis Vaccines and Diagnostics175
进行中（未招募）
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.Chronic Lymphocytic LeukemiaEUCTR2016-001097-15-BGAbbVie Deutschland GmbH & Co. KG200
已完成
3 期
Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL)Cancer of the blood10024324LeukemiaNL-OMON55465AbbVie B.V.8
进行中（未招募）
1 期
A study evaluating venetoclax (ABT-199) in subjects with Chronic Lymphocytic Leukemia (CLL) whose cancer has come back or who had no response to previous cancer treatments.MedDRA version: 20.0Level: PTClassification code 10008958Term: Chronic lymphocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Chronic Lymphocytic LeukemiaEUCTR2016-001097-15-HUAbbVie Deutschland GmbH & Co. KG200